** Shares of Starpharma Holdings fall as much as 2.2% to A$0.091, their lowest level since Sept. 11
** Biopharmaceutical co withdraws marketing authorisation application for SPL7013 nasal spray with Australia's Therapeutic Goods Administration
** SPL7013 is an antiviral spray for protection against COVID-19
** Co says withdrawal after a more than three-year application and review process that consumed significant internal resources
** About 1.5 mln shares change hands, 3 times the 30-day avg of 478,000 shares
** Starpharma down 45.9% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。